Skip to main content
All lobbying filings

NOVARTIS

Lobbying for NOVARTIS

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $4,168,000.00 expenses · posted Apr 21, 2025

Official filing document

 Bills named in this filing 13
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1095
    Stop STALLING Act
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • HR 946
    ORPHAN Cures Act
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
  • S 864
    HELP Copays Act
  • HR 2214
    DRUG Act
  • HR 950
    Saving Seniors Money on Prescriptions Act
  • S 832
    EPIC Act of 2025
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1672
    Maintaining Investments in New Innovation Act
  • HR 2425
    Kairo Act of 2025
 Lobbying activity 7
Budget/Appropriations

2025 Appropriations Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act FY 2025 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Federal Budget Reconciliation 2026 Appropriations

Copyright/Patent/Trademark

S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues

Health Issues

340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program Accelerated Approval Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues H.R.946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion

Medicare/Medicaid

H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues

Taxation/Internal Revenue Code

Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Tax Relief for American Families and Workers Act Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97

Trade (domestic/foreign)

Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Labor Issues/Antitrust/Workplace

Anti-Trust Reform

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem